We provide evidence that reducing the distribution of drugs (e.g diclofenac) with proven CV risk in the heart using nanoparticles will reduce their CV complications without compromising the efficacy.
Tags: Bio-Tech, Med-Tech, Health Sciences.
You need to be logged in to use this feature.
Hanan Al Lawati
We provide evidence that reducing the distribution of drugs (e.g diclofenac) with proven CV risk in the heart using nanoparticles will reduce their CV complications without compromising the efficacy.
Tags: Bio-Tech, Med-Tech, Health Sciences.
Hanan Al Lawati is an academic faculty member at the Oman College of Health Sciences, Ministry of Health. She completed her PhD studies in 2019 at the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, Edmonton, Canada. Hanan’s research has been very well received by the scientific community in Canada and has helped her win several research funding awards. She has recently received ‘The Research Council National Research Award’. Hanan has authored eight peer-reviewed articles and has delivered several posters and oral presentations at international conferences.